High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Lilly’s drug for advanced pancreatic cancer.
Eli Lilly stock has delivered very strong gains over the past five years, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable gap below the current price while the broader scorecard still leans expensive. Eli Lilly has returned about 357.2% over five years, which puts extra focus on whether the current price already reflects investors' optimism. The FDA's Breakthrough Therapy designation for olomorasib can...
Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.
SpaceX reports second-quarter results, new GLP-1s are coming, latest ‘Spider-Man’ pushes Hollywood toward record haul, and more news to start your day.
The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.
The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.
With American alcohol consumption near historic lows, Boston Beer Company is fighting an uphill battle.
Key Takeaways; Cannabis Sector Vireo Growth to Acquire Planet 13 in Landmark All-Stock Deal SNDL Completed Parallel Asset Acquisition, Expanding its U.S. Medical Cannabis Footprint Tilray Posted Record FY2026 Revenue as Cannabis Sales Rose and Losses Narrowed Key Takeaways; Psychedelic Sector Eli Lilly’s $3.8 Billion Deal to Acquire AtaiBeckley Signals a Major Push into Psychedelic-Inspired […]
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.
Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...
And it will likely be the first company in the sector to get there.
The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Companies that have reported in the Q2 cycle are offering encouraging reads on order trends, margin resilience, and full-year demand. This fundamental health is filtering directly into analyst models, driving a steady stream of upward revisions for Q3 and beyond.
Most of what Cramer says on the "Mad Money" Lightning Round is fast and directional. Occasionally, he drops a framework that reveals how he actually thinks about investing, not just trading. When a caller asked about Eli Lilly (LLY) on Tuesday, July 28, Cramer did not give a buy or sell, according ...
The global market for obesity drugs is soaring, yet Lilly has a dominant market share.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
